The restructuring is aimed at freeing up resources so the firm can advance its EBV-positive peripheral T-cell lymphoma drug toward the market.

NEW YORK – Researchers at the University of California, San Francisco hope to establish new prostate-specific antigen (PSA) cut-off values for prostate cancer screening in transgender women after a ...

NEW YORK – Cel-Sci on Thursday said the US Food and Drug Administration agreed with its plan to select head and neck cancer patients with low PD-L1 tumor expression in a confirmatory registrational ...

SRP-5051 is designed to bind to exon 51 of dystrophin pre-mRNA, resulting in exclusion of this exon during mRNA processing in patients with genetic mutations amenable to exon 51 skipping. With this ...

The company will use the proceeds to develop its gene therapies for eye disorders and for general corporate expenses.

The funding will allow CUH to buy new equipment for administering treatments such as CAR T-cell therapies, reducing patients' need to travel long distances.

Merus expects the FDA to make a decision on the application in February after reviewing additional manufacturing information it submitted.

Based on early Phase I/II trial data, Tango has decided to end enrollment in a study of TNG908 and focus resources on more promising drugs in its pipeline.

After years of persistence, genetic counselors at UT Southwestern got BCBS of Texas to fix a system error that was leading to payment denials for services.

In JAMA Neurology, the group challenged the "movement" to define Alzheimer's disease as a "purely biological entity based on biomarker findings." ...

The partners will use Inify's AI platform to identify potentially cancerous regions in prostate cancer biopsy images within Karolinska's ProMort program.

National Cancer Center Japan has partnered with Precision Medicine Asia and Paradigm Health to develop a streamlined system to facilitate trials.